Kezar Life Sciences Inc | Needs refresh | Last updated: 2026-03-29T08:34:16Z
Kezar Life Sciences Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for KZR-261 Trial in serious or life-threatening diseases outside (Approved).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| KZR-261 | Advanced/Metastatic Solid Tumor | n/a | Phase 1 | Public pipeline row |
| KZR-261 Trial | serious or life-threatening diseases outside | n/a | Approved | Public pipeline row |
| KZR-616 | Polymyositis | Dermatomyositis | n/a | Phase 2 | Public pipeline row |
| zetomipzomib | Autoimmune Hepatitis | n/a | Phase 2 | Public pipeline row |
No public catalyst rows matched this view yet.
Estimated cash runway: Runway > 12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT04039477 | Phase 2 | WITHDRAWN | n/a | 2020-08-05 |
| NCT04033926 | Phase 2 | COMPLETED | 25 | 2022-04-06 |
| NCT03393013 | Phase 1 | Phase 2 | COMPLETED | 69 | 2022-08-04 |
| NCT04628936 | Phase 2 | COMPLETED | 18 | 2023-03-10 |
| NCT05781750 | Phase 2 | TERMINATED | 84 | 2024-11-08 |
| NCT05047536 | Phase 1 | TERMINATED | 61 | 2025-01-17 |
| NCT05569759 | Phase 2 | COMPLETED | 24 | 2025-04-30 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.